Free papers |
|
| |
1. Contingency Management for the Treatment of Substance Use Disorders: Enhancing Access, Quality, and Program Integrity for an Evidence-Based Intervention Contingency Management for the Treatment of Substance Use Disorders: Enhancing Access, Quality, and Program Integrity for an Evidence-Based Intervention-/-HHS ASPE Reports 2024; ? (?): ? | | *39250570* 39250570 | |
2. Matching-adjusted indirect comparison of Acalabrutinib versus Ibrutinib in relapsed/refractory mantle cell lymphoma. J Med Econ 2024; ? (?): 1-8 | | *39461001* 39461001 | |
PMC11512600 3. Pregnancy impacts allergy-related differences in the response to a type-1 stimulus, staphylococcal enterotoxin A. Clin Transl Allergy 2024; 14 (10): e70007 | | *39460995* 39460995 | |
4. Association of SOGPI in mediating the effect of Phosphatidylcholine on polycystic Ovary Syndrome. Gynecol Endocrinol 2024; 40 (1): 2420963 | | *39460994* 39460994 | |
5. MK-801-exposure induces increased translation efficiency and mRNA hyperacetylation of Grin2a in the mouse prefrontal cortex. Epigenetics 2024; 19 (1): 2417158 | | *39460980* 39460980 | |
6. Familial osteochondrodysplastic and cardiomyopathic syndrome in Chianina cattle. J Vet Intern Med 2024; ? (?): ? | | *39460958* 39460958 | |
7. Transcatheter aortic valve replacement failure: surgical valve explantation after more than a decade. Interdiscip Cardiovasc Thorac Surg 2024; ? (?): ? | | *39460950* 39460950 | |
8. Protocol to profile spatially resolved NLRP3 inflammasome complexes using APEX2-based proximity labeling. STAR Protoc 2024; 5 (4): 103417 | | *39460941* 39460941 | |
9. Protocol for analyzing the function of the type VI secretion system of the oral symbiont Aggregatibacter aphrophilus in targeting pathobionts. STAR Protoc 2024; 5 (4): 103415 | | *39460940* 39460940 | |
10. Paired C-type lectin receptors mediate specific recognition of divergent oomycete pathogens in C. elegans. Cell Rep 2024; 43 (11): 114906 | | *39460939* 39460939 | |
11. General anesthesia activates a central anxiolytic center in the BNST. Cell Rep 2024; 43 (11): 114909 | | *39460938* 39460938 | |
12. Deep proteomic analysis of microglia reveals fundamental biological differences between model systems. Cell Rep 2024; 43 (11): 114908 | | *39460937* 39460937 | |
PMC11512480 13. vEMstitch: an algorithm for fully automatic image stitching of volume electron microscopy. Gigascience 2024; 13 (?): ? | | *39460935* 39460935 | |
PMC11512451 14. Discovering genotype-phenotype relationships with machine learning and the Visual Physiology Opsin Database (VPOD). Gigascience 2024; 13 (?): ? | | *39460934* 39460934 | |
15. Reevaluating Informed Consent: Integrating Shared Decision-Making into Spinal Surgery for Better Patient Outcomes. Global Spine J 2024; ? (?): 21925682241298228 | | *39460929* 39460929 | |
PMC11514817 16. Probing atomic-scale processes at the ferrihydrite-water interface with reactive molecular dynamics. Geochem Trans 2024; 25 (1): 10 | | *39460808* 39460808 | |
17. Promoting equality in utilization of basic public health services in China: The role of the family doctor contract service. J Med Econ 2024; ? (?): 1-21 | | *39460743* 39460743 | |
PMC11512511 18. Assessing the transcriptional landscape of Pseudomonas phage 201varphi2-1: Uncovering the small regulatory details of a giant phage. Microb Biotechnol 2024; 17 (10): e70037 | | *39460739* 39460739 | |
19. Evolution of mate harm resistance in females from Drosophila melanogaster populations selected for faster development and early reproduction. J Evol Biol 2024; ? (?): ? | | *39460733* 39460733 | |
20. Subcutaneous ocrelizumab in multiple sclerosis: Results of the Phase 1b OCARINA I study. Ann Clin Transl Neurol 2024; ? (?): ? | | *39460719* 39460719 | |
21. Impact of the socioeconomic crisis in Lebanon on people with epilepsy. Epilepsia Open 2024; ? (?): ? | | *39460690* 39460690 | |
22. The burst of satellite DNA in Leptidea wood white butterflies and their putative role in karyotype evolution. DNA Res 2024; ? (?): ? | | *39460673* 39460673 | |
23. Identifying DNA Variants in a Turkish Cohort with Inner Ear Anomalies. Ear Nose Throat J 2024; ? (?): 1455613241287290 | | *39460668* 39460668 | |
24. Evaluation of the Educational Quality of Endonasal Endoscopic Dacryocystorhinostomy Videos on YouTube with IVORY and LAP-VEGaS Guidelines. Ear Nose Throat J 2024; ? (?): 1455613241293867 | | *39460661* 39460661 | |
PMC11512438 25. Comparison of the Effectiveness of Warmed Versus Room Temperature Intravenous Fluids Administration to Prevent Intraoperative Heat Loss in Anaesthetised Calves Undergoing Umbilical Herniorrhaphy. Vet Med Sci 2024; 10 (6): e70096 | | *39460658* 39460658 | |
PMC11512436 26. Stability of Sodium Pentobarbital 5w/v% Aqueous Solution During Short-Term Chilled and Ambient-Temperature Storage. Vet Med Sci 2024; 10 (6): e70066 | | *39460652* 39460652 | |
27. The Effect of Postural Rehabilitation on Pain, Balance, Mandibular Movement, and Posture in Temporomandibular Disorder Patients: A Comparison Between Posterior Edentulous and Dentate Groups. Ear Nose Throat J 2024; ? (?): 1455613241291713 | | *39460584* 39460584 | |
28. Incretin hormones: Revolutionizing the treatment landscape for kidney and liver diseases in type 2 diabetes and obesity. J Diabetes Investig 2024; ? (?): ? | | *39460581* 39460581 | |
29. Effects of development and parental care on Hamilton's force of selection. J Evol Biol 2024; ? (?): ? | | *39460578* 39460578 | |
30. Mechanical loading-induced alveolar bone remodeling is suppressed in the diabetic state via the impairment of the specificity protein 1/vascular endothelial growth factor (SP1/VEGF) axis. J Diabetes Investig 2024; ? (?): ? | | *39460577* 39460577 | |
31. Association between malnutrition and adverse renal outcomes in patients with type 2 diabetes. J Diabetes Investig 2024; ? (?): ? | | *39460574* 39460574 | |
32. Intravenous thrombolysis or antiplatelet therapy for acute nondisabling ischemic stroke: A systematic review and network meta-analysis. Eur Stroke J 2024; ? (?): 23969873241293323 | | *39460567* 39460567 | |
33. Antithrombotic drugs for carotid artery dissection: Updated systematic review. Eur Stroke J 2024; ? (?): 23969873241292278 | | *39460559* 39460559 | |
PMC11514409 34. Informing factors and outcomes of self-assessment practices in medical education: a systematic review. Ann Med 2024; 56 (1): 2421441 | | *39460558* 39460558 | |
PMC11514391 35. Psychological predictors of incident subjective cognitive complaints in community dwelling older adults. Ann Med 2024; 56 (1): 2421443 | | *39460556* 39460556 | |
PMC11514389 36. Clinicopathological characteristics and genomic profiling in patients with transformed lymphoma: a monocentric retrospective study. Ann Med 2024; 56 (1): 2419556 | | *39460552* 39460552 | |
PMC11514392 37. Diversity of heart failure phenotypes in transthyretin amyloid cardiomyopathy. More than just heart failure with preserved ejection fraction. Ann Med 2024; 56 (1): 2418965 | | *39460551* 39460551 | |
PMC11514388 38. Diagnostic accuracy of FibroScan-AST (FAST) score, non-alcoholic fatty liver fibrosis score (NFS), FibroScan, and liver fibrosis index (FIB-4) for identifying fibrotic non-alcoholic steatohepatitis in patients with chronic hepatitis B with metabolic dysfunction-associated fatty liver disease. Ann Med 2024; 56 (1): 2420858 | | *39460547* 39460547 | |
39. Impressions about harm are formed rapidly and then refined, modulated by serotonin. Soc Cogn Affect Neurosci 2024; ? (?): ? | | *39460542* 39460542 | |
40. Informing the risk assessment related to lactation and drug exposure: A physiologically based pharmacokinetic lactation model for pregabalin. CPT Pharmacometrics Syst Pharmacol 2024; ? (?): ? | | *39460526* 39460526 | |
41. The magnitude of parental physical harms: a descriptive report of 76 abusive children in Isfahan. J Inj Violence Res 2024; 16 (2): ? | | *39460512* 39460512 | |
42. Real-world predictors of severe psychological distress during the COVID-19 pandemic in Japan: Insights from a large-scale internet-based cohort study. Neuropsychopharmacol Rep 2024; ? (?): ? | | *39460501* 39460501 | |
PMC11514122 43. The Effects of Coffee/Caffeine in Patients with Multiple Sclerosis; A Systematic Review. J Evid Based Integr Med 2024; 29 (?): 2515690X241293114 | | *39460478* 39460478 | |
44. Highly Active and Durable Nanostructured Nickel-Molybdenum Coatings as Hydrogen Electrocatalysts via Solution Precursor Plasma Spraying. ChemistryOpen 2024; ? (?): e202400069 | | *39460467* 39460467 | |
45. Comment on: 'Reduced Temporal Muscle Thickness Predicts Shorter Survival in Patients Undergoing Chronic Subdural Haematoma Drainage' by Korhonen et al. J Cachexia Sarcopenia Muscle 2024; ? (?): ? | | *39460450* 39460450 | |
46. Molecular Engineering L-Aspartate-Alpha-Decarboxylase to Enhance Catalytic Stability and Performance. ChemistryOpen 2024; ? (?): e202400236 | | *39460447* 39460447 | |
47. Enhancing the Interfacial Property Between UHMWPE Fibers and Epoxy Through Polydopamine and SiO(2) Surface Modification. ChemistryOpen 2024; ? (?): e202400131 | | *39460445* 39460445 | |
48. Anxiolytic Efficacy of Indirubin: In Vivo Approach Along with Receptor Binding Profiling and Molecular Interaction with GABAergic Pathways. ChemistryOpen 2024; ? (?): e202400290 | | *39460441* 39460441 | |
49. Rapid and Environmentally-Friendly Synthesis of Thiazolidinone Analogues in Deep Eutectic Solvent Complemented with Computational Studies. ChemistryOpen 2024; ? (?): e202400198 | | *39460430* 39460430 | |
50. Efficient Cleavage of pUC19 DNA by Tetraaminonaphthols. ChemistryOpen 2024; ? (?): e202400157 | | *39460429* 39460429 | |
51. Human papillomavirus vaccine to prevent CIN3 or worse (CIN3+): A nationwide case-control study in Japan. Cancer Sci 2024; ? (?): ? | | *39460387* 39460387 | |
52. The Application of Artificial Intelligence in Lung Cancer Research. Cancer Control 2024; 31 (?): 10732748241297373 | | *39460384* 39460384 | |
PMC11511775 53. Serum antibodies against mimotopes of Merkel cell polyomavirus oncoproteins detected by a novel immunoassay in healthy individuals and Merkel cell carcinoma patients. Microb Biotechnol 2024; 17 (10): e14536 | | *39460382* 39460382 | |
54. Early resilience and epigenetic ageing: Results from the prospective Young Finns Study with a 31-year follow-up. Aging Cell 2024; ? (?): e14394 | | *39460379* 39460379 | |
PMC11511440 55. Correction: Rothen et al. Preclinical Evaluation of Novel Sterically Optimized VLP-Based Vaccines against All Four DENV Serotypes. Vaccines 2024, 12, 874. Vaccines (Basel) 2024; 12 (10): ? | | *39460367* 39460367 | |
PMC11492804 56. Correction: Khan et al. Oral Immunization of Chickens with Probiotic Lactobacillus crispatus Constitutively Expressing the alpha-beta2-epsilon-beta1 Toxoids to Induce Protective Immunity. Vaccines 2022, 10, 698. Vaccines (Basel) 2024; 12 (10): ? | | *39460366* 39460366 | |
PMC11512205 57. Comparative Analysis of the Neutralizing Capacity of Monovalent and Bivalent Formulations of Betuvax-CoV-2, a Subunit Recombinant COVID-19 Vaccine, Against Various Strains of SARS-CoV-2. Vaccines (Basel) 2024; 12 (10): ? | | *39460365* 39460365 | |
PMC11511582 58. Interferon Epsilon-Mediated Antiviral Activity Against Human Metapneumovirus and Respiratory Syncytial Virus. Vaccines (Basel) 2024; 12 (10): ? | | *39460364* 39460364 | |
PMC11512415 59. Impact of Infections During Pregnancy on Transplacental Antibody Transfer. Vaccines (Basel) 2024; 12 (10): ? | | *39460363* 39460363 | |
PMC11511336 60. Burden of Pneumococcal Disease in Young Children Due to Serotypes Contained in Different Pneumococcal Conjugate Vaccines in Eight Asian Countries and Territories. Vaccines (Basel) 2024; 12 (10): ? | | *39460362* 39460362 | |
PMC11511213 61. The Global Burden of Absenteeism Related to COVID-19 Vaccine Side Effects Among Healthcare Workers: A Systematic Review and Meta-Analysis. Vaccines (Basel) 2024; 12 (10): ? | | *39460361* 39460361 | |
PMC11512341 62. Comparative Efficacy of Parenteral and Mucosal Recombinant Probiotic Vaccines Against SARS-CoV-2 and S. pneumoniae Infections in Animal Models. Vaccines (Basel) 2024; 12 (10): ? | | *39460360* 39460360 | |
PMC11511229 63. Identifying System-Level Strategies to Engage in HPV Prevention Across Oral Health and Primary Care Settings. Vaccines (Basel) 2024; 12 (10): ? | | *39460359* 39460359 | |
PMC11512328 64. Myocarditis Associated with COVID-19 Vaccination. Vaccines (Basel) 2024; 12 (10): ? | | *39460358* 39460358 | |
PMC11511359 65. Pertussis Outbreak During 2023 in Gipuzkoa, North Spain. Vaccines (Basel) 2024; 12 (10): ? | | *39460357* 39460357 | |
PMC11511174 66. Intranasal Prime-Boost with Spike Vectors Generates Antibody and T-Cell Responses at the Site of SARS-CoV-2 Infection. Vaccines (Basel) 2024; 12 (10): ? | | *39460356* 39460356 | |
PMC11512354 67. Impact of Immunosuppressants and Vaccination on COVID-19 Outcomes in Autoimmune Patients and Solid Organ Transplant Recipients: A Nationwide Propensity Score-Matched Study. Vaccines (Basel) 2024; 12 (10): ? | | *39460355* 39460355 | |
PMC11511444 68. Partial Protection of Goats against Haemonchus contortus Achieved with ADP-Ribosylation Factor 1 Encapsulated in PLGA Nanoparticles. Vaccines (Basel) 2024; 12 (10): ? | | *39460354* 39460354 | |
PMC11512336 69. Nationwide Discrete Choice Experiment on Chinese Guardians' Preferences for HPV Vaccination for Mothers and Daughters. Vaccines (Basel) 2024; 12 (10): ? | | *39460353* 39460353 | |
PMC11511158 70. Basic Properties and Development Status of Aluminum Adjuvants Used for Vaccines. Vaccines (Basel) 2024; 12 (10): ? | | *39460352* 39460352 | |
PMC11511424 71. Effect of Vaccination Against E. coli, C. perfringens Type A/C on Piglet Productive and Clinical Parameters Under Field Conditions. Vaccines (Basel) 2024; 12 (10): ? | | *39460351* 39460351 | |
PMC11512427 72. Incremental Effectiveness of Emergency Vaccination Against a Varicella Outbreak at an Elementary School in Beijing, China, 2019: An Observational Cohort Study. Vaccines (Basel) 2024; 12 (10): ? | | *39460350* 39460350 | |
PMC11511404 73. ASIA Syndrome: State-of-the-Art and Future Perspectives. Vaccines (Basel) 2024; 12 (10): ? | | *39460349* 39460349 | |
PMC11512391 74. Mixed Th1/Th2/Th17 Responses Induced by Plant Oil Adjuvant-Based B. bronchiseptica Vaccine in Mice, with Mechanisms Unraveled by RNA-Seq, 16S rRNA and Metabolomics. Vaccines (Basel) 2024; 12 (10): ? | | *39460348* 39460348 | |
PMC11511246 75. T-Cell Epitope-Based Vaccines: A Promising Strategy for Prevention of Infectious Diseases. Vaccines (Basel) 2024; 12 (10): ? | | *39460347* 39460347 | |
PMC11511555 76. What COVID-19 Vaccination Strategy Should Be Implemented and Which Vaccines Should Be Used in the Post-Pandemic Era? Vaccines (Basel) 2024; 12 (10): ? | | *39460346* 39460346 | |
PMC11511131 77. Immunotherapeutic Strategies as Potential Treatment Options for Cutaneous Leishmaniasis. Vaccines (Basel) 2024; 12 (10): ? | | *39460345* 39460345 | |
PMC11512348 78. Overview of Recombinant Tick Vaccines and Perspectives on the Use of Plant-Made Vaccines to Control Ticks of Veterinary Importance. Vaccines (Basel) 2024; 12 (10): ? | | *39460344* 39460344 | |
PMC11512408 79. Klebsiella pneumoniae Lipopolysaccharide as a Vaccine Target and the Role of Antibodies in Protection from Disease. Vaccines (Basel) 2024; 12 (10): ? | | *39460343* 39460343 | |
PMC11511486 80. Antiretroviral Therapy with Ritonavir-Boosted Atazanavir- and Lopinavir-Containing Regimens Correlates with Diminished HIV-1 Neutralization. Vaccines (Basel) 2024; 12 (10): ? | | *39460342* 39460342 | |
PMC11511137 81. Reply to Volkman et al. Comment on "Fust et al. The Potential Economic Impact of the Updated COVID-19 mRNA Fall 2023 Vaccines in Japan. Vaccines 2024, 12, 434". Vaccines (Basel) 2024; 12 (10): ? | | *39460341* 39460341 | |
PMC11512365 82. Comment on Fust et al. The Potential Economic Impact of the Updated COVID-19 mRNA Fall 2023 Vaccines in Japan. Vaccines 2024, 12, 434. Vaccines (Basel) 2024; 12 (10): ? | | *39460340* 39460340 | |
PMC11512252 83. Field Trial with Vaccine Candidates Against Bovine Tuberculosis Among Likely Infected Cattle in a Natural Transmission Setting. Vaccines (Basel) 2024; 12 (10): ? | | *39460339* 39460339 | |
PMC11512344 84. Immunogenicity and Determinants of Antibody Response to the BNT162b2 mRNA Vaccine: A Longitudinal Study in a Cohort of People Living with HIV. Vaccines (Basel) 2024; 12 (10): ? | | *39460338* 39460338 | |
PMC11511307 85. Intranasal Trans-Sialidase Vaccine Mitigates Acute and Chronic Pathology in a Preclinical Oral Chagas Disease Model. Vaccines (Basel) 2024; 12 (10): ? | | *39460337* 39460337 | |
PMC11511343 86. Evaluation of a Low-Temperature Immersion Immunization Strategy for the Infectious Spleen and Kidney Necrosis Virus orf037l Gene-Deleted Attenuated Vaccine. Vaccines (Basel) 2024; 12 (10): ? | | *39460336* 39460336 | |
PMC11511243 87. Knowledge, Attitudes, and Practices towards Influenza Vaccine among Guangzhou Residents: A Cross-Sectional Study. Vaccines (Basel) 2024; 12 (10): ? | | *39460335* 39460335 | |
PMC11511428 88. Kaposi Sarcoma as a Possible Cutaneous Adverse Effect of ChAdOx1 nCov-19 Vaccine: A Case Report. Vaccines (Basel) 2024; 12 (10): ? | | *39460334* 39460334 | |
PMC11512251 89. The Recent Research Progress of the Tumor mRNA Vaccine. Vaccines (Basel) 2024; 12 (10): ? | | *39460333* 39460333 | |
PMC11511198 90. Effect of EV71 Vaccination on Transmission Dynamics of Hand, Foot, and Mouth Disease and Its Epidemic Prevention Threshold. Vaccines (Basel) 2024; 12 (10): ? | | *39460332* 39460332 | |
PMC11512403 91. Does the Vaccination against Tick-Borne Encephalitis Offer Good Value for Money for Incidence Rates below the WHO Threshold for Endemicity? A Case Study for Germany. Vaccines (Basel) 2024; 12 (10): ? | | *39460331* 39460331 | |
PMC11511354 92. Comparison of Predictive Factors of Flu Vaccine Uptake Pre- and Post-COVID-19 Using the NIS-Teen Survey. Vaccines (Basel) 2024; 12 (10): ? | | *39460330* 39460330 | |
PMC11512203 93. SARS-CoV-2 Vaccination in Patients with Cancer and COVID-19 in Mexico. Vaccines (Basel) 2024; 12 (10): ? | | *39460329* 39460329 | |
PMC11511366 94. Analyzing Changes in Attitudes and Behaviors towards Seasonal Influenza Vaccination in Spain's Adult Population over Three Seasons. Vaccines (Basel) 2024; 12 (10): ? | | *39460328* 39460328 | |
PMC11511100 95. Modelling the Relative Vaccine Efficacy of ARCT-154, a Self-Amplifying mRNA COVID-19 Vaccine, versus BNT162b2 Using Immunogenicity Data. Vaccines (Basel) 2024; 12 (10): ? | | *39460327* 39460327 | |
PMC11510999 96. Evaluating the Effectiveness of Nirsevimab in Reducing Pediatric RSV Hospitalizations in Spain. Vaccines (Basel) 2024; 12 (10): ? | | *39460326* 39460326 | |
PMC11511161 97. Local Inflammatory and Systemic Antibody Responses Initiated by a First Intradermal Administration of Autogenous Salmonella-Killed Vaccines and Their Components in Pullets. Vaccines (Basel) 2024; 12 (10): ? | | *39460325* 39460325 | |
PMC11510991 98. Did We Overreact? Insights on COVID-19 Disease and Vaccination in a Large Cohort of Immune-Mediated Inflammatory Disease Patients during Sequential Phases of the Pandemic (The BELCOMID Study). Vaccines (Basel) 2024; 12 (10): ? | | *39460324* 39460324 | |
PMC11512317 99. Anti-HBs Seroprevalence in Blood Donors from Tyrol, Austria. Vaccines (Basel) 2024; 12 (10): ? | | *39460323* 39460323 | |
PMC11512279 100. A Head-to-Head Comparative Study of the Replication-Competent Vaccinia Virus and AAV1-Based Malaria Vaccine versus RTS,S/AS01 in Murine Models. Vaccines (Basel) 2024; 12 (10): ? | | *39460322* 39460322 | |
PMC11511042 101. HPV Vaccination Status in HIV-Negative MSM and Its Association with High-Risk HPV Detection Using HPV Serology and Anorectal Swabs. Vaccines (Basel) 2024; 12 (10): ? | | *39460321* 39460321 | |
PMC11511206 102. Acceptance of Rubella-Containing Vaccine and Factors Associated with Acceptance among Women of Reproductive Age in China: A Cross-Sectional Study. Vaccines (Basel) 2024; 12 (10): ? | | *39460320* 39460320 | |
PMC11512357 103. Immunogenicity and Protectivity of Sputnik V Vaccine in hACE2-Transgenic Mice against Homologous and Heterologous SARS-CoV-2 Lineages Including Far-Distanced Omicron BA.5. Vaccines (Basel) 2024; 12 (10): ? | | *39460319* 39460319 | |
PMC11511517 104. Mobile Phone Text Message Reminders to Improve Vaccination Uptake: A Systematic Review and Meta-Analysis. Vaccines (Basel) 2024; 12 (10): ? | | *39460318* 39460318 | |
PMC11511590 105. Clustering Analysis Identified Distinct Clinical Phenotypes among Hemodialysis Patients in Their Immunological Response to the BNT162b2 mRNA Vaccine against SARS-CoV-2. Vaccines (Basel) 2024; 12 (10): ? | | *39460317* 39460317 | |
PMC11512233 106. Symptomatology and IgG Levels before and after SARS-CoV-2 Omicron Breakthrough Infections in Vaccinated Individuals. Vaccines (Basel) 2024; 12 (10): ? | | *39460316* 39460316 | |
PMC11510967 107. Recent Advances in Lipid Nanoparticles and Their Safety Concerns for mRNA Delivery. Vaccines (Basel) 2024; 12 (10): ? | | *39460315* 39460315 | |
PMC11511175 108. Vaccination for Mpox (Monkeypox) Infection in Humans: From Basic Science to Real-World Effectiveness. Vaccines (Basel) 2024; 12 (10): ? | | *39460314* 39460314 | |
PMC11511558 109. Network Analysis of Dysregulated Immune Response to COVID-19 mRNA Vaccination in Hemodialysis Patients. Vaccines (Basel) 2024; 12 (10): ? | | *39460313* 39460313 | |
PMC11511252 110. Trends of Diphtheria-Tetanus-Pertussis and Measles Vaccine Coverage Preceding and during the COVID-19 Pandemic: An Analysis of the WHO European Region from 2000 to 2022. Vaccines (Basel) 2024; 12 (10): ? | | *39460312* 39460312 | |
PMC11511549 111. Analytical Performance of a Multiplexed Microarray Assay for Rapid Identification and Quantification of a Multivalent mRNA Vaccine. Vaccines (Basel) 2024; 12 (10): ? | | *39460311* 39460311 | |
PMC11511576 112. Attitudes towards Maternal Immunisation of Polish Mothers: A Cross-Sectional, Non-Representative Study. Vaccines (Basel) 2024; 12 (10): ? | | *39460310* 39460310 | |
PMC11511542 113. The Peculiar Emergence of Mpox (Monkeypox): Directions for the Search for the Natural Reservoir and Vaccination Strategies. Vaccines (Basel) 2024; 12 (10): ? | | *39460309* 39460309 | |
PMC11512296 114. Understanding Vaccine Hesitancy: A Comparison of Sociodemographic and Socioeconomic Predictors with Health Literacy Dimensions. Vaccines (Basel) 2024; 12 (10): ? | | *39460308* 39460308 | |
PMC11511104 115. Evaluation of the Safety and Immunogenicity of a Multiple Epitope Polypeptide from Canine Distemper Virus (CDV) in Mice. Vaccines (Basel) 2024; 12 (10): ? | | *39460307* 39460307 | |
PMC11510871 116. Truncated VZV gE Induces High-Titer Neutralizing Antibodies in Mice. Vaccines (Basel) 2024; 12 (10): ? | | *39460306* 39460306 | |
PMC11511248 117. Efficacy and Safety in Dogs Following Administration of an Alphavirus RNA Particle Canine Influenza H3N2 Vaccine. Vaccines (Basel) 2024; 12 (10): ? | | *39460305* 39460305 | |
PMC11511094 118. Generational Factors Associated with SARS-CoV-2 Vaccine Completion for Americans of Mexican Decent Living along the United States-Mexico Border Region. Vaccines (Basel) 2024; 12 (10): ? | | *39460304* 39460304 | |
PMC11511116 119. Safety and Humoral Immunogenicity of Different Dose Levels of Ad26.COV2.S as a 2-Dose Regimen in COVID-19 Vaccine-Naive Healthy Adults: A Phase 3 Randomized Clinical Trial. Vaccines (Basel) 2024; 12 (10): ? | | *39460303* 39460303 | |
PMC11510881 120. The Influence of Initial Immunosuppression on the Kinetics of Humoral Response after SARS-CoV-2 Vaccination in Patients Undergoing Kidney Transplantation. Vaccines (Basel) 2024; 12 (10): ? | | *39460302* 39460302 | |
PMC11512284 121. CT584 Is Not a Protective Vaccine Antigen against Respiratory Chlamydial Challenge in Mice. Vaccines (Basel) 2024; 12 (10): ? | | *39460301* 39460301 | |
PMC11511092 122. Spectrum and Incidence of Adverse Reactions Post Immunization in the Taiwanese Population (2014-2019): An Analysis Using the National Vaccine Injury Compensation Program. Vaccines (Basel) 2024; 12 (10): ? | | *39460300* 39460300 | |
PMC11511423 123. Maternal Preconception COVID-19 Vaccination and Its Protective Effect on Infants after a Breakthrough Infection during Pregnancy. Vaccines (Basel) 2024; 12 (10): ? | | *39460299* 39460299 | |
PMC11511038 124. Using Behavior Integration to Identify Barriers and Motivators for COVID-19 Vaccination and Build a Vaccine Demand and Confidence Strategy in Southeastern Europe. Vaccines (Basel) 2024; 12 (10): ? | | *39460298* 39460298 | |
PMC11511525 125. Postpartum Interventions to Increase Maternal Vaccination Uptake: Is It Worth It? Vaccines (Basel) 2024; 12 (10): ? | | *39460297* 39460297 | |
PMC11511431 126. Mtb-Specific HLA-E-Restricted T Cells Are Induced during Mtb Infection but Not after BCG Administration in Non-Human Primates and Humans. Vaccines (Basel) 2024; 12 (10): ? | | *39460296* 39460296 | |
PMC11512426 127. Drivers of COVID-19 Vaccination among Eligible Adults in Abuja, Nigeria: A Mixed-Methods Study Using the WHO Behavioral and Social Drivers of Vaccination Framework. Vaccines (Basel) 2024; 12 (10): ? | | *39460295* 39460295 | |
PMC11511495 128. Novel Mouse Model of Recurrent Sublethal Herpes Simplex Virus Infection Recapitulates Human Antibody Responses to Primary and Chronic Infection. Vaccines (Basel) 2024; 12 (10): ? | | *39460294* 39460294 | |
PMC11511197 129. T-Cell Immune Responses to SARS-CoV-2 Infection and Vaccination. Vaccines (Basel) 2024; 12 (10): ? | | *39460293* 39460293 | |
PMC11511218 130. Generation and Genetic Stability of a PolX and 5' MGF-Deficient African Swine Fever Virus Mutant for Vaccine Development. Vaccines (Basel) 2024; 12 (10): ? | | *39460292* 39460292 | |
PMC11511380 131. Influenza Vaccine Effectiveness against Influenza A-Associated Outpatient and Emergency-Department-Attended Influenza-like Illness during the Delayed 2022-2023 Season in Beijing, China. Vaccines (Basel) 2024; 12 (10): ? | | *39460291* 39460291 | |
PMC11511130 132. The PreS-Based Recombinant Vaccine VVX001 Induces Hepatitis B Virus Neutralizing Antibodies in a Low-Responder to HBsAg-Based HBV Vaccines. Vaccines (Basel) 2024; 12 (10): ? | | *39460290* 39460290 | |
PMC11511157 133. Vaccines Hesitancy and Public Health. Vaccines (Basel) 2024; 12 (10): ? | | *39460289* 39460289 | |
PMC11510850 134. Sequential Immune Acquisition of Monoclonal Antibodies Enhances Phagocytosis of Acinetobacter baumannii by Recognizing ATP Synthase. Vaccines (Basel) 2024; 12 (10): ? | | *39460288* 39460288 | |
PMC11511251 135. A Polysaccharide-Based Oral-Vaccine Delivery System and Adjuvant for the Influenza Virus Vaccine. Vaccines (Basel) 2024; 12 (10): ? | | *39460287* 39460287 | |
PMC11511301 136. Detection of PCV2d in Vaccinated Pigs in Colombia and Prediction of Vaccine T Cell Epitope Coverage against Circulating Strains Using EpiCC Analysis. Vaccines (Basel) 2024; 12 (10): ? | | *39460286* 39460286 | |
PMC11511304 137. HPV Vaccination Coverage in Brazil's State of Parana: Spatial Distribution and Advances in Public Health. Vaccines (Basel) 2024; 12 (10): ? | | *39460285* 39460285 | |
PMC11511097 138. Toxicity and Efficacy Evaluation of Soluble Recombinant Ricin Vaccine. Vaccines (Basel) 2024; 12 (10): ? | | *39460284* 39460284 | |
PMC11511529 139. Comparative Ability of Various Immunosuppressants as Adjuvants on the Activity of T1D Vaccine. Vaccines (Basel) 2024; 12 (10): ? | | *39460283* 39460283 | |
PMC11511345 140. Enhanced Expression of the L1R Gene of Vaccinia Virus by the tPA Signal Sequence Inserted in a Fowlpox-Based Recombinant Vaccine. Vaccines (Basel) 2024; 12 (10): ? | | *39460282* 39460282 | |
PMC11511409 141. Genotype II Live-Attenuated ASFV Vaccine Strains Unable to Completely Protect Pigs against the Emerging Recombinant ASFV Genotype I/II Strain in Vietnam. Vaccines (Basel) 2024; 12 (10): ? | | *39460281* 39460281 | |
PMC11511569 142. Cost-Effectiveness of Influenza Vaccination in Healthy Children: A 10-Year Population-Based Study. Vaccines (Basel) 2024; 12 (10): ? | | *39460280* 39460280 | |
PMC11511493 143. Ferritin Vaccine Platform for Animal and Zoonotic Viruses. Vaccines (Basel) 2024; 12 (10): ? | | *39460279* 39460279 | |
PMC11511291 144. Structures of the Varicella Zoster Virus Glycoprotein E and Epitope Mapping of Vaccine-Elicited Antibodies. Vaccines (Basel) 2024; 12 (10): ? | | *39460278* 39460278 | |
PMC11511309 145. Position Statement about Gender-Neutral HPV Vaccination in Korea. Vaccines (Basel) 2024; 12 (10): ? | | *39460277* 39460277 | |
PMC11510771 146. Immunogenicity and Safety of Omicron-Containing Multivalent COVID-19 Vaccines in Unvaccinated and Previously Vaccinated Adults. Vaccines (Basel) 2024; 12 (10): ? | | *39460276* 39460276 | |
PMC11511443 147. Reproducibility Assessment of Enzyme-Linked Immunosorbent Assays to Detect Anti-HPV16 L1-Specific IgG1, IgG3, IgA, and IgM Antibodies. Vaccines (Basel) 2024; 12 (10): ? | | *39460275* 39460275 | |
PMC11511346 148. Comparative Effectiveness of the Bivalent (Original/Omicron BA.4/BA.5) mRNA COVID-19 Vaccines mRNA-1273.222 and BNT162b2 Bivalent in Adults with Underlying Medical Conditions in the United States. Vaccines (Basel) 2024; 12 (10): ? | | *39460274* 39460274 | |
PMC11511289 149. Immune Responses to Methicillin-Resistant Staphylococcus aureus Infections and Advances in the Development of Vaccines and Immunotherapies. Vaccines (Basel) 2024; 12 (10): ? | | *39460273* 39460273 | |
PMC11511386 150. A New Licensed Quadrivalent Antileptospiral Canine Vaccine Prevents Mortality, Clinical Signs, Infection, Bacterial Excretion, Renal Carriage and Renal Lesions Caused by Leptospira Australis Experimental Challenge. Vaccines (Basel) 2024; 12 (10): ? | | *39460272* 39460272 | |
151. Contingency Management for the Treatment of Substance Use Disorders: Enhancing Access, Quality, and Program Integrity for an Evidence-Based Intervention Contingency Management for the Treatment of Substance Use Disorders: Enhancing Access, Quality, and Program Integrity for an Evidence-Based Intervention-/-HHS ASPE Reports 2024; ? (?): ? | | *39250570* 39250570 | |
152. Matching-adjusted indirect comparison of Acalabrutinib versus Ibrutinib in relapsed/refractory mantle cell lymphoma. J Med Econ 2024; ? (?): 1-8 | | *39461001* 39461001 | |
PMC11512600 153. Pregnancy impacts allergy-related differences in the response to a type-1 stimulus, staphylococcal enterotoxin A. Clin Transl Allergy 2024; 14 (10): e70007 | | *39460995* 39460995 | |
154. Association of SOGPI in mediating the effect of Phosphatidylcholine on polycystic Ovary Syndrome. Gynecol Endocrinol 2024; 40 (1): 2420963 | | *39460994* 39460994 | |
155. MK-801-exposure induces increased translation efficiency and mRNA hyperacetylation of Grin2a in the mouse prefrontal cortex. Epigenetics 2024; 19 (1): 2417158 | | *39460980* 39460980 | |
156. Familial osteochondrodysplastic and cardiomyopathic syndrome in Chianina cattle. J Vet Intern Med 2024; ? (?): ? | | *39460958* 39460958 | |
157. Transcatheter aortic valve replacement failure: surgical valve explantation after more than a decade. Interdiscip Cardiovasc Thorac Surg 2024; ? (?): ? | | *39460950* 39460950 | |
158. Protocol to profile spatially resolved NLRP3 inflammasome complexes using APEX2-based proximity labeling. STAR Protoc 2024; 5 (4): 103417 | | *39460941* 39460941 | |
159. Protocol for analyzing the function of the type VI secretion system of the oral symbiont Aggregatibacter aphrophilus in targeting pathobionts. STAR Protoc 2024; 5 (4): 103415 | | *39460940* 39460940 | |
160. Paired C-type lectin receptors mediate specific recognition of divergent oomycete pathogens in C. elegans. Cell Rep 2024; 43 (11): 114906 | | *39460939* 39460939 | |
161. General anesthesia activates a central anxiolytic center in the BNST. Cell Rep 2024; 43 (11): 114909 | | *39460938* 39460938 | |
162. Deep proteomic analysis of microglia reveals fundamental biological differences between model systems. Cell Rep 2024; 43 (11): 114908 | | *39460937* 39460937 | |
PMC11512480 163. vEMstitch: an algorithm for fully automatic image stitching of volume electron microscopy. Gigascience 2024; 13 (?): ? | | *39460935* 39460935 | |
PMC11512451 164. Discovering genotype-phenotype relationships with machine learning and the Visual Physiology Opsin Database (VPOD). Gigascience 2024; 13 (?): ? | | *39460934* 39460934 | |
165. Reevaluating Informed Consent: Integrating Shared Decision-Making into Spinal Surgery for Better Patient Outcomes. Global Spine J 2024; ? (?): 21925682241298228 | | *39460929* 39460929 | |
PMC11514817 166. Probing atomic-scale processes at the ferrihydrite-water interface with reactive molecular dynamics. Geochem Trans 2024; 25 (1): 10 | | *39460808* 39460808 | |
167. Promoting equality in utilization of basic public health services in China: The role of the family doctor contract service. J Med Econ 2024; ? (?): 1-21 | | *39460743* 39460743 | |
PMC11512511 168. Assessing the transcriptional landscape of Pseudomonas phage 201varphi2-1: Uncovering the small regulatory details of a giant phage. Microb Biotechnol 2024; 17 (10): e70037 | | *39460739* 39460739 | |
169. Evolution of mate harm resistance in females from Drosophila melanogaster populations selected for faster development and early reproduction. J Evol Biol 2024; ? (?): ? | | *39460733* 39460733 | |
170. Subcutaneous ocrelizumab in multiple sclerosis: Results of the Phase 1b OCARINA I study. Ann Clin Transl Neurol 2024; ? (?): ? | | *39460719* 39460719 | |
171. Impact of the socioeconomic crisis in Lebanon on people with epilepsy. Epilepsia Open 2024; ? (?): ? | | *39460690* 39460690 | |
172. The burst of satellite DNA in Leptidea wood white butterflies and their putative role in karyotype evolution. DNA Res 2024; ? (?): ? | | *39460673* 39460673 | |
173. Identifying DNA Variants in a Turkish Cohort with Inner Ear Anomalies. Ear Nose Throat J 2024; ? (?): 1455613241287290 | | *39460668* 39460668 | |
174. Evaluation of the Educational Quality of Endonasal Endoscopic Dacryocystorhinostomy Videos on YouTube with IVORY and LAP-VEGaS Guidelines. Ear Nose Throat J 2024; ? (?): 1455613241293867 | | *39460661* 39460661 | |
PMC11512438 175. Comparison of the Effectiveness of Warmed Versus Room Temperature Intravenous Fluids Administration to Prevent Intraoperative Heat Loss in Anaesthetised Calves Undergoing Umbilical Herniorrhaphy. Vet Med Sci 2024; 10 (6): e70096 | | *39460658* 39460658 | |
PMC11512436 176. Stability of Sodium Pentobarbital 5w/v% Aqueous Solution During Short-Term Chilled and Ambient-Temperature Storage. Vet Med Sci 2024; 10 (6): e70066 | | *39460652* 39460652 | |
177. The Effect of Postural Rehabilitation on Pain, Balance, Mandibular Movement, and Posture in Temporomandibular Disorder Patients: A Comparison Between Posterior Edentulous and Dentate Groups. Ear Nose Throat J 2024; ? (?): 1455613241291713 | | *39460584* 39460584 | |
178. Incretin hormones: Revolutionizing the treatment landscape for kidney and liver diseases in type 2 diabetes and obesity. J Diabetes Investig 2024; ? (?): ? | | *39460581* 39460581 | |
179. Effects of development and parental care on Hamilton's force of selection. J Evol Biol 2024; ? (?): ? | | *39460578* 39460578 | |
180. Mechanical loading-induced alveolar bone remodeling is suppressed in the diabetic state via the impairment of the specificity protein 1/vascular endothelial growth factor (SP1/VEGF) axis. J Diabetes Investig 2024; ? (?): ? | | *39460577* 39460577 | |
181. Association between malnutrition and adverse renal outcomes in patients with type 2 diabetes. J Diabetes Investig 2024; ? (?): ? | | *39460574* 39460574 | |
182. Intravenous thrombolysis or antiplatelet therapy for acute nondisabling ischemic stroke: A systematic review and network meta-analysis. Eur Stroke J 2024; ? (?): 23969873241293323 | | *39460567* 39460567 | |
183. Antithrombotic drugs for carotid artery dissection: Updated systematic review. Eur Stroke J 2024; ? (?): 23969873241292278 | | *39460559* 39460559 | |
PMC11514409 184. Informing factors and outcomes of self-assessment practices in medical education: a systematic review. Ann Med 2024; 56 (1): 2421441 | | *39460558* 39460558 | |
PMC11514391 185. Psychological predictors of incident subjective cognitive complaints in community dwelling older adults. Ann Med 2024; 56 (1): 2421443 | | *39460556* 39460556 | |
PMC11514389 186. Clinicopathological characteristics and genomic profiling in patients with transformed lymphoma: a monocentric retrospective study. Ann Med 2024; 56 (1): 2419556 | | *39460552* 39460552 | |
PMC11514392 187. Diversity of heart failure phenotypes in transthyretin amyloid cardiomyopathy. More than just heart failure with preserved ejection fraction. Ann Med 2024; 56 (1): 2418965 | | *39460551* 39460551 | |
PMC11514388 188. Diagnostic accuracy of FibroScan-AST (FAST) score, non-alcoholic fatty liver fibrosis score (NFS), FibroScan, and liver fibrosis index (FIB-4) for identifying fibrotic non-alcoholic steatohepatitis in patients with chronic hepatitis B with metabolic dysfunction-associated fatty liver disease. Ann Med 2024; 56 (1): 2420858 | | *39460547* 39460547 | |
189. Impressions about harm are formed rapidly and then refined, modulated by serotonin. Soc Cogn Affect Neurosci 2024; ? (?): ? | | *39460542* 39460542 | |
190. Informing the risk assessment related to lactation and drug exposure: A physiologically based pharmacokinetic lactation model for pregabalin. CPT Pharmacometrics Syst Pharmacol 2024; ? (?): ? | | *39460526* 39460526 | |
191. The magnitude of parental physical harms: a descriptive report of 76 abusive children in Isfahan. J Inj Violence Res 2024; 16 (2): ? | | *39460512* 39460512 | |
192. Real-world predictors of severe psychological distress during the COVID-19 pandemic in Japan: Insights from a large-scale internet-based cohort study. Neuropsychopharmacol Rep 2024; ? (?): ? | | *39460501* 39460501 | |
PMC11514122 193. The Effects of Coffee/Caffeine in Patients with Multiple Sclerosis; A Systematic Review. J Evid Based Integr Med 2024; 29 (?): 2515690X241293114 | | *39460478* 39460478 | |
194. Highly Active and Durable Nanostructured Nickel-Molybdenum Coatings as Hydrogen Electrocatalysts via Solution Precursor Plasma Spraying. ChemistryOpen 2024; ? (?): e202400069 | | *39460467* 39460467 | |
195. Comment on: 'Reduced Temporal Muscle Thickness Predicts Shorter Survival in Patients Undergoing Chronic Subdural Haematoma Drainage' by Korhonen et al. J Cachexia Sarcopenia Muscle 2024; ? (?): ? | | *39460450* 39460450 | |
196. Molecular Engineering L-Aspartate-Alpha-Decarboxylase to Enhance Catalytic Stability and Performance. ChemistryOpen 2024; ? (?): e202400236 | | *39460447* 39460447 | |
197. Enhancing the Interfacial Property Between UHMWPE Fibers and Epoxy Through Polydopamine and SiO(2) Surface Modification. ChemistryOpen 2024; ? (?): e202400131 | | *39460445* 39460445 | |
198. Anxiolytic Efficacy of Indirubin: In Vivo Approach Along with Receptor Binding Profiling and Molecular Interaction with GABAergic Pathways. ChemistryOpen 2024; ? (?): e202400290 | | *39460441* 39460441 | |
199. Rapid and Environmentally-Friendly Synthesis of Thiazolidinone Analogues in Deep Eutectic Solvent Complemented with Computational Studies. ChemistryOpen 2024; ? (?): e202400198 | | *39460430* 39460430 | |
200. Efficient Cleavage of pUC19 DNA by Tetraaminonaphthols. ChemistryOpen 2024; ? (?): e202400157 | | *39460429* 39460429 | |
201. Human papillomavirus vaccine to prevent CIN3 or worse (CIN3+): A nationwide case-control study in Japan. Cancer Sci 2024; ? (?): ? | | *39460387* 39460387 | |
202. The Application of Artificial Intelligence in Lung Cancer Research. Cancer Control 2024; 31 (?): 10732748241297373 | | *39460384* 39460384 | |
PMC11511775 203. Serum antibodies against mimotopes of Merkel cell polyomavirus oncoproteins detected by a novel immunoassay in healthy individuals and Merkel cell carcinoma patients. Microb Biotechnol 2024; 17 (10): e14536 | | *39460382* 39460382 | |
204. Early resilience and epigenetic ageing: Results from the prospective Young Finns Study with a 31-year follow-up. Aging Cell 2024; ? (?): e14394 | | *39460379* 39460379 | |
PMC11511440 205. Correction: Rothen et al. Preclinical Evaluation of Novel Sterically Optimized VLP-Based Vaccines against All Four DENV Serotypes. Vaccines 2024, 12, 874. Vaccines (Basel) 2024; 12 (10): ? | | *39460367* 39460367 | |
PMC11492804 206. Correction: Khan et al. Oral Immunization of Chickens with Probiotic Lactobacillus crispatus Constitutively Expressing the alpha-beta2-epsilon-beta1 Toxoids to Induce Protective Immunity. Vaccines 2022, 10, 698. Vaccines (Basel) 2024; 12 (10): ? | | *39460366* 39460366 | |
PMC11512205 207. Comparative Analysis of the Neutralizing Capacity of Monovalent and Bivalent Formulations of Betuvax-CoV-2, a Subunit Recombinant COVID-19 Vaccine, Against Various Strains of SARS-CoV-2. Vaccines (Basel) 2024; 12 (10): ? | | *39460365* 39460365 | |
PMC11511582 208. Interferon Epsilon-Mediated Antiviral Activity Against Human Metapneumovirus and Respiratory Syncytial Virus. Vaccines (Basel) 2024; 12 (10): ? | | *39460364* 39460364 | |
PMC11512415 209. Impact of Infections During Pregnancy on Transplacental Antibody Transfer. Vaccines (Basel) 2024; 12 (10): ? | | *39460363* 39460363 | |
PMC11511336 210. Burden of Pneumococcal Disease in Young Children Due to Serotypes Contained in Different Pneumococcal Conjugate Vaccines in Eight Asian Countries and Territories. Vaccines (Basel) 2024; 12 (10): ? | | *39460362* 39460362 | |
PMC11511213 211. The Global Burden of Absenteeism Related to COVID-19 Vaccine Side Effects Among Healthcare Workers: A Systematic Review and Meta-Analysis. Vaccines (Basel) 2024; 12 (10): ? | | *39460361* 39460361 | |
PMC11512341 212. Comparative Efficacy of Parenteral and Mucosal Recombinant Probiotic Vaccines Against SARS-CoV-2 and S. pneumoniae Infections in Animal Models. Vaccines (Basel) 2024; 12 (10): ? | | *39460360* 39460360 | |
PMC11511229 213. Identifying System-Level Strategies to Engage in HPV Prevention Across Oral Health and Primary Care Settings. Vaccines (Basel) 2024; 12 (10): ? | | *39460359* 39460359 | |
PMC11512328 214. Myocarditis Associated with COVID-19 Vaccination. Vaccines (Basel) 2024; 12 (10): ? | | *39460358* 39460358 | |
PMC11511359 215. Pertussis Outbreak During 2023 in Gipuzkoa, North Spain. Vaccines (Basel) 2024; 12 (10): ? | | *39460357* 39460357 | |
PMC11511174 216. Intranasal Prime-Boost with Spike Vectors Generates Antibody and T-Cell Responses at the Site of SARS-CoV-2 Infection. Vaccines (Basel) 2024; 12 (10): ? | | *39460356* 39460356 | |
PMC11512354 217. Impact of Immunosuppressants and Vaccination on COVID-19 Outcomes in Autoimmune Patients and Solid Organ Transplant Recipients: A Nationwide Propensity Score-Matched Study. Vaccines (Basel) 2024; 12 (10): ? | | *39460355* 39460355 | |
PMC11511444 218. Partial Protection of Goats against Haemonchus contortus Achieved with ADP-Ribosylation Factor 1 Encapsulated in PLGA Nanoparticles. Vaccines (Basel) 2024; 12 (10): ? | | *39460354* 39460354 | |
PMC11512336 219. Nationwide Discrete Choice Experiment on Chinese Guardians' Preferences for HPV Vaccination for Mothers and Daughters. Vaccines (Basel) 2024; 12 (10): ? | | *39460353* 39460353 | |
PMC11511158 220. Basic Properties and Development Status of Aluminum Adjuvants Used for Vaccines. Vaccines (Basel) 2024; 12 (10): ? | | *39460352* 39460352 | |
PMC11511424 221. Effect of Vaccination Against E. coli, C. perfringens Type A/C on Piglet Productive and Clinical Parameters Under Field Conditions. Vaccines (Basel) 2024; 12 (10): ? | | *39460351* 39460351 | |
PMC11512427 222. Incremental Effectiveness of Emergency Vaccination Against a Varicella Outbreak at an Elementary School in Beijing, China, 2019: An Observational Cohort Study. Vaccines (Basel) 2024; 12 (10): ? | | *39460350* 39460350 | |
PMC11511404 223. ASIA Syndrome: State-of-the-Art and Future Perspectives. Vaccines (Basel) 2024; 12 (10): ? | | *39460349* 39460349 | |
PMC11512391 224. Mixed Th1/Th2/Th17 Responses Induced by Plant Oil Adjuvant-Based B. bronchiseptica Vaccine in Mice, with Mechanisms Unraveled by RNA-Seq, 16S rRNA and Metabolomics. Vaccines (Basel) 2024; 12 (10): ? | | *39460348* 39460348 | |
PMC11511246 225. T-Cell Epitope-Based Vaccines: A Promising Strategy for Prevention of Infectious Diseases. Vaccines (Basel) 2024; 12 (10): ? | | *39460347* 39460347 | |
PMC11511555 226. What COVID-19 Vaccination Strategy Should Be Implemented and Which Vaccines Should Be Used in the Post-Pandemic Era? Vaccines (Basel) 2024; 12 (10): ? | | *39460346* 39460346 | |
PMC11511131 227. Immunotherapeutic Strategies as Potential Treatment Options for Cutaneous Leishmaniasis. Vaccines (Basel) 2024; 12 (10): ? | | *39460345* 39460345 | |
PMC11512348 228. Overview of Recombinant Tick Vaccines and Perspectives on the Use of Plant-Made Vaccines to Control Ticks of Veterinary Importance. Vaccines (Basel) 2024; 12 (10): ? | | *39460344* 39460344 | |
PMC11512408 229. Klebsiella pneumoniae Lipopolysaccharide as a Vaccine Target and the Role of Antibodies in Protection from Disease. Vaccines (Basel) 2024; 12 (10): ? | | *39460343* 39460343 | |
PMC11511486 230. Antiretroviral Therapy with Ritonavir-Boosted Atazanavir- and Lopinavir-Containing Regimens Correlates with Diminished HIV-1 Neutralization. Vaccines (Basel) 2024; 12 (10): ? | | *39460342* 39460342 | |
PMC11511137 231. Reply to Volkman et al. Comment on "Fust et al. The Potential Economic Impact of the Updated COVID-19 mRNA Fall 2023 Vaccines in Japan. Vaccines 2024, 12, 434". Vaccines (Basel) 2024; 12 (10): ? | | *39460341* 39460341 | |
PMC11512365 232. Comment on Fust et al. The Potential Economic Impact of the Updated COVID-19 mRNA Fall 2023 Vaccines in Japan. Vaccines 2024, 12, 434. Vaccines (Basel) 2024; 12 (10): ? | | *39460340* 39460340 | |
PMC11512252 233. Field Trial with Vaccine Candidates Against Bovine Tuberculosis Among Likely Infected Cattle in a Natural Transmission Setting. Vaccines (Basel) 2024; 12 (10): ? | | *39460339* 39460339 | |
PMC11512344 234. Immunogenicity and Determinants of Antibody Response to the BNT162b2 mRNA Vaccine: A Longitudinal Study in a Cohort of People Living with HIV. Vaccines (Basel) 2024; 12 (10): ? | | *39460338* 39460338 | |
PMC11511307 235. Intranasal Trans-Sialidase Vaccine Mitigates Acute and Chronic Pathology in a Preclinical Oral Chagas Disease Model. Vaccines (Basel) 2024; 12 (10): ? | | *39460337* 39460337 | |
PMC11511343 236. Evaluation of a Low-Temperature Immersion Immunization Strategy for the Infectious Spleen and Kidney Necrosis Virus orf037l Gene-Deleted Attenuated Vaccine. Vaccines (Basel) 2024; 12 (10): ? | | *39460336* 39460336 | |
PMC11511243 237. Knowledge, Attitudes, and Practices towards Influenza Vaccine among Guangzhou Residents: A Cross-Sectional Study. Vaccines (Basel) 2024; 12 (10): ? | | *39460335* 39460335 | |
PMC11511428 238. Kaposi Sarcoma as a Possible Cutaneous Adverse Effect of ChAdOx1 nCov-19 Vaccine: A Case Report. Vaccines (Basel) 2024; 12 (10): ? | | *39460334* 39460334 | |
PMC11512251 239. The Recent Research Progress of the Tumor mRNA Vaccine. Vaccines (Basel) 2024; 12 (10): ? | | *39460333* 39460333 | |
PMC11511198 240. Effect of EV71 Vaccination on Transmission Dynamics of Hand, Foot, and Mouth Disease and Its Epidemic Prevention Threshold. Vaccines (Basel) 2024; 12 (10): ? | | *39460332* 39460332 | |
PMC11512403 241. Does the Vaccination against Tick-Borne Encephalitis Offer Good Value for Money for Incidence Rates below the WHO Threshold for Endemicity? A Case Study for Germany. Vaccines (Basel) 2024; 12 (10): ? | | *39460331* 39460331 | |
PMC11511354 242. Comparison of Predictive Factors of Flu Vaccine Uptake Pre- and Post-COVID-19 Using the NIS-Teen Survey. Vaccines (Basel) 2024; 12 (10): ? | | *39460330* 39460330 | |
PMC11512203 243. SARS-CoV-2 Vaccination in Patients with Cancer and COVID-19 in Mexico. Vaccines (Basel) 2024; 12 (10): ? | | *39460329* 39460329 | |
PMC11511366 244. Analyzing Changes in Attitudes and Behaviors towards Seasonal Influenza Vaccination in Spain's Adult Population over Three Seasons. Vaccines (Basel) 2024; 12 (10): ? | | *39460328* 39460328 | |
PMC11511100 245. Modelling the Relative Vaccine Efficacy of ARCT-154, a Self-Amplifying mRNA COVID-19 Vaccine, versus BNT162b2 Using Immunogenicity Data. Vaccines (Basel) 2024; 12 (10): ? | | *39460327* 39460327 | |
PMC11510999 246. Evaluating the Effectiveness of Nirsevimab in Reducing Pediatric RSV Hospitalizations in Spain. Vaccines (Basel) 2024; 12 (10): ? | | *39460326* 39460326 | |
PMC11511161 247. Local Inflammatory and Systemic Antibody Responses Initiated by a First Intradermal Administration of Autogenous Salmonella-Killed Vaccines and Their Components in Pullets. Vaccines (Basel) 2024; 12 (10): ? | | *39460325* 39460325 | |
PMC11510991 248. Did We Overreact? Insights on COVID-19 Disease and Vaccination in a Large Cohort of Immune-Mediated Inflammatory Disease Patients during Sequential Phases of the Pandemic (The BELCOMID Study). Vaccines (Basel) 2024; 12 (10): ? | | *39460324* 39460324 | |
PMC11512317 249. Anti-HBs Seroprevalence in Blood Donors from Tyrol, Austria. Vaccines (Basel) 2024; 12 (10): ? | | *39460323* 39460323 | |
PMC11512279 250. A Head-to-Head Comparative Study of the Replication-Competent Vaccinia Virus and AAV1-Based Malaria Vaccine versus RTS,S/AS01 in Murine Models. Vaccines (Basel) 2024; 12 (10): ? | | *39460322* 39460322 | |
PMC11511042 251. HPV Vaccination Status in HIV-Negative MSM and Its Association with High-Risk HPV Detection Using HPV Serology and Anorectal Swabs. Vaccines (Basel) 2024; 12 (10): ? | | *39460321* 39460321 | |
PMC11511206 252. Acceptance of Rubella-Containing Vaccine and Factors Associated with Acceptance among Women of Reproductive Age in China: A Cross-Sectional Study. Vaccines (Basel) 2024; 12 (10): ? | | *39460320* 39460320 | |
PMC11512357 253. Immunogenicity and Protectivity of Sputnik V Vaccine in hACE2-Transgenic Mice against Homologous and Heterologous SARS-CoV-2 Lineages Including Far-Distanced Omicron BA.5. Vaccines (Basel) 2024; 12 (10): ? | | *39460319* 39460319 | |
PMC11511517 254. Mobile Phone Text Message Reminders to Improve Vaccination Uptake: A Systematic Review and Meta-Analysis. Vaccines (Basel) 2024; 12 (10): ? | | *39460318* 39460318 | |
PMC11511590 255. Clustering Analysis Identified Distinct Clinical Phenotypes among Hemodialysis Patients in Their Immunological Response to the BNT162b2 mRNA Vaccine against SARS-CoV-2. Vaccines (Basel) 2024; 12 (10): ? | | *39460317* 39460317 | |
PMC11512233 256. Symptomatology and IgG Levels before and after SARS-CoV-2 Omicron Breakthrough Infections in Vaccinated Individuals. Vaccines (Basel) 2024; 12 (10): ? | | *39460316* 39460316 | |
PMC11510967 257. Recent Advances in Lipid Nanoparticles and Their Safety Concerns for mRNA Delivery. Vaccines (Basel) 2024; 12 (10): ? | | *39460315* 39460315 | |
PMC11511175 258. Vaccination for Mpox (Monkeypox) Infection in Humans: From Basic Science to Real-World Effectiveness. Vaccines (Basel) 2024; 12 (10): ? | | *39460314* 39460314 | |
PMC11511558 259. Network Analysis of Dysregulated Immune Response to COVID-19 mRNA Vaccination in Hemodialysis Patients. Vaccines (Basel) 2024; 12 (10): ? | | *39460313* 39460313 | |
PMC11511252 260. Trends of Diphtheria-Tetanus-Pertussis and Measles Vaccine Coverage Preceding and during the COVID-19 Pandemic: An Analysis of the WHO European Region from 2000 to 2022. Vaccines (Basel) 2024; 12 (10): ? | | *39460312* 39460312 | |
PMC11511549 261. Analytical Performance of a Multiplexed Microarray Assay for Rapid Identification and Quantification of a Multivalent mRNA Vaccine. Vaccines (Basel) 2024; 12 (10): ? | | *39460311* 39460311 | |
PMC11511576 262. Attitudes towards Maternal Immunisation of Polish Mothers: A Cross-Sectional, Non-Representative Study. Vaccines (Basel) 2024; 12 (10): ? | | *39460310* 39460310 | |
PMC11511542 263. The Peculiar Emergence of Mpox (Monkeypox): Directions for the Search for the Natural Reservoir and Vaccination Strategies. Vaccines (Basel) 2024; 12 (10): ? | | *39460309* 39460309 | |
PMC11512296 264. Understanding Vaccine Hesitancy: A Comparison of Sociodemographic and Socioeconomic Predictors with Health Literacy Dimensions. Vaccines (Basel) 2024; 12 (10): ? | | *39460308* 39460308 | |
PMC11511104 265. Evaluation of the Safety and Immunogenicity of a Multiple Epitope Polypeptide from Canine Distemper Virus (CDV) in Mice. Vaccines (Basel) 2024; 12 (10): ? | | *39460307* 39460307 | |
PMC11510871 266. Truncated VZV gE Induces High-Titer Neutralizing Antibodies in Mice. Vaccines (Basel) 2024; 12 (10): ? | | *39460306* 39460306 | |
PMC11511248 267. Efficacy and Safety in Dogs Following Administration of an Alphavirus RNA Particle Canine Influenza H3N2 Vaccine. Vaccines (Basel) 2024; 12 (10): ? | | *39460305* 39460305 | |
PMC11511094 268. Generational Factors Associated with SARS-CoV-2 Vaccine Completion for Americans of Mexican Decent Living along the United States-Mexico Border Region. Vaccines (Basel) 2024; 12 (10): ? | | *39460304* 39460304 | |
PMC11511116 269. Safety and Humoral Immunogenicity of Different Dose Levels of Ad26.COV2.S as a 2-Dose Regimen in COVID-19 Vaccine-Naive Healthy Adults: A Phase 3 Randomized Clinical Trial. Vaccines (Basel) 2024; 12 (10): ? | | *39460303* 39460303 | |
PMC11510881 270. The Influence of Initial Immunosuppression on the Kinetics of Humoral Response after SARS-CoV-2 Vaccination in Patients Undergoing Kidney Transplantation. Vaccines (Basel) 2024; 12 (10): ? | | *39460302* 39460302 | |
PMC11512284 271. CT584 Is Not a Protective Vaccine Antigen against Respiratory Chlamydial Challenge in Mice. Vaccines (Basel) 2024; 12 (10): ? | | *39460301* 39460301 | |
PMC11511092 272. Spectrum and Incidence of Adverse Reactions Post Immunization in the Taiwanese Population (2014-2019): An Analysis Using the National Vaccine Injury Compensation Program. Vaccines (Basel) 2024; 12 (10): ? | | *39460300* 39460300 | |
PMC11511423 273. Maternal Preconception COVID-19 Vaccination and Its Protective Effect on Infants after a Breakthrough Infection during Pregnancy. Vaccines (Basel) 2024; 12 (10): ? | | *39460299* 39460299 | |
PMC11511038 274. Using Behavior Integration to Identify Barriers and Motivators for COVID-19 Vaccination and Build a Vaccine Demand and Confidence Strategy in Southeastern Europe. Vaccines (Basel) 2024; 12 (10): ? | | *39460298* 39460298 | |
PMC11511525 275. Postpartum Interventions to Increase Maternal Vaccination Uptake: Is It Worth It? Vaccines (Basel) 2024; 12 (10): ? | | *39460297* 39460297 | |
PMC11511431 276. Mtb-Specific HLA-E-Restricted T Cells Are Induced during Mtb Infection but Not after BCG Administration in Non-Human Primates and Humans. Vaccines (Basel) 2024; 12 (10): ? | | *39460296* 39460296 | |
PMC11512426 277. Drivers of COVID-19 Vaccination among Eligible Adults in Abuja, Nigeria: A Mixed-Methods Study Using the WHO Behavioral and Social Drivers of Vaccination Framework. Vaccines (Basel) 2024; 12 (10): ? | | *39460295* 39460295 | |
PMC11511495 278. Novel Mouse Model of Recurrent Sublethal Herpes Simplex Virus Infection Recapitulates Human Antibody Responses to Primary and Chronic Infection. Vaccines (Basel) 2024; 12 (10): ? | | *39460294* 39460294 | |
PMC11511197 279. T-Cell Immune Responses to SARS-CoV-2 Infection and Vaccination. Vaccines (Basel) 2024; 12 (10): ? | | *39460293* 39460293 | |
PMC11511218 280. Generation and Genetic Stability of a PolX and 5' MGF-Deficient African Swine Fever Virus Mutant for Vaccine Development. Vaccines (Basel) 2024; 12 (10): ? | | *39460292* 39460292 | |
PMC11511380 281. Influenza Vaccine Effectiveness against Influenza A-Associated Outpatient and Emergency-Department-Attended Influenza-like Illness during the Delayed 2022-2023 Season in Beijing, China. Vaccines (Basel) 2024; 12 (10): ? | | *39460291* 39460291 | |
PMC11511130 282. The PreS-Based Recombinant Vaccine VVX001 Induces Hepatitis B Virus Neutralizing Antibodies in a Low-Responder to HBsAg-Based HBV Vaccines. Vaccines (Basel) 2024; 12 (10): ? | | *39460290* 39460290 | |
PMC11511157 283. Vaccines Hesitancy and Public Health. Vaccines (Basel) 2024; 12 (10): ? | | *39460289* 39460289 | |
PMC11510850 284. Sequential Immune Acquisition of Monoclonal Antibodies Enhances Phagocytosis of Acinetobacter baumannii by Recognizing ATP Synthase. Vaccines (Basel) 2024; 12 (10): ? | | *39460288* 39460288 | |
PMC11511251 285. A Polysaccharide-Based Oral-Vaccine Delivery System and Adjuvant for the Influenza Virus Vaccine. Vaccines (Basel) 2024; 12 (10): ? | | *39460287* 39460287 | |
PMC11511301 286. Detection of PCV2d in Vaccinated Pigs in Colombia and Prediction of Vaccine T Cell Epitope Coverage against Circulating Strains Using EpiCC Analysis. Vaccines (Basel) 2024; 12 (10): ? | | *39460286* 39460286 | |
PMC11511304 287. HPV Vaccination Coverage in Brazil's State of Parana: Spatial Distribution and Advances in Public Health. Vaccines (Basel) 2024; 12 (10): ? | | *39460285* 39460285 | |
PMC11511097 288. Toxicity and Efficacy Evaluation of Soluble Recombinant Ricin Vaccine. Vaccines (Basel) 2024; 12 (10): ? | | *39460284* 39460284 | |
PMC11511529 289. Comparative Ability of Various Immunosuppressants as Adjuvants on the Activity of T1D Vaccine. Vaccines (Basel) 2024; 12 (10): ? | | *39460283* 39460283 | |
PMC11511345 290. Enhanced Expression of the L1R Gene of Vaccinia Virus by the tPA Signal Sequence Inserted in a Fowlpox-Based Recombinant Vaccine. Vaccines (Basel) 2024; 12 (10): ? | | *39460282* 39460282 | |
PMC11511409 291. Genotype II Live-Attenuated ASFV Vaccine Strains Unable to Completely Protect Pigs against the Emerging Recombinant ASFV Genotype I/II Strain in Vietnam. Vaccines (Basel) 2024; 12 (10): ? | | *39460281* 39460281 | |
PMC11511569 292. Cost-Effectiveness of Influenza Vaccination in Healthy Children: A 10-Year Population-Based Study. Vaccines (Basel) 2024; 12 (10): ? | | *39460280* 39460280 | |
PMC11511493 293. Ferritin Vaccine Platform for Animal and Zoonotic Viruses. Vaccines (Basel) 2024; 12 (10): ? | | *39460279* 39460279 | |
PMC11511291 294. Structures of the Varicella Zoster Virus Glycoprotein E and Epitope Mapping of Vaccine-Elicited Antibodies. Vaccines (Basel) 2024; 12 (10): ? | | *39460278* 39460278 | |
PMC11511309 295. Position Statement about Gender-Neutral HPV Vaccination in Korea. Vaccines (Basel) 2024; 12 (10): ? | | *39460277* 39460277 | |
PMC11510771 296. Immunogenicity and Safety of Omicron-Containing Multivalent COVID-19 Vaccines in Unvaccinated and Previously Vaccinated Adults. Vaccines (Basel) 2024; 12 (10): ? | | *39460276* 39460276 | |
PMC11511443 297. Reproducibility Assessment of Enzyme-Linked Immunosorbent Assays to Detect Anti-HPV16 L1-Specific IgG1, IgG3, IgA, and IgM Antibodies. Vaccines (Basel) 2024; 12 (10): ? | | *39460275* 39460275 | |
PMC11511346 298. Comparative Effectiveness of the Bivalent (Original/Omicron BA.4/BA.5) mRNA COVID-19 Vaccines mRNA-1273.222 and BNT162b2 Bivalent in Adults with Underlying Medical Conditions in the United States. Vaccines (Basel) 2024; 12 (10): ? | | *39460274* 39460274 | |
PMC11511289 299. Immune Responses to Methicillin-Resistant Staphylococcus aureus Infections and Advances in the Development of Vaccines and Immunotherapies. Vaccines (Basel) 2024; 12 (10): ? | | *39460273* 39460273 | |
PMC11511386 300. A New Licensed Quadrivalent Antileptospiral Canine Vaccine Prevents Mortality, Clinical Signs, Infection, Bacterial Excretion, Renal Carriage and Renal Lesions Caused by Leptospira Australis Experimental Challenge. Vaccines (Basel) 2024; 12 (10): ? | | *39460272* 39460272 | |
|
|